Adult-onset Still's disease and tocilizumab Archives

Abstract Number: 253 • ACR/ARHP Annual Meeting 2016
Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month
Tsuneo Kondo¹, Yusuke Okada², Akiko Shibata¹, Kentaro Chino¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Background/Purpose: To assess the efficacy and safety of tocilizumab (TCZ) monotherapy for the induction therapy of adult onset Still’s disease (AOSD) in a prospective, single-arm, single-center, cohort,…
Abstract Number: 266 • ACR/ARHP Annual Meeting 2015
Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases
Seung Taek Song¹, Jin Ju Kim², Seung Lee¹, Hye-Jin Jeong¹, Il Woong Sohn², Sung Won Lee², Joo Hyun Lee³, Hyoun-Ah Kim⁴, Kwang-Hoon Lee⁵, Sang Tae Choi⁶, Eun Young Lee⁷, Kichul Shin⁸, Hoon-Suk Cha⁹ and Dae-Hyun Yoo¹⁰, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Rheumatology, Ilsan Paik Hospital, Inje University, Goyang, South Korea, ⁴Ajou University Hospital, Suwon, South Korea, ⁵Dongguk University Ilsan Hospital, Goyang, South Korea, ⁶Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea, ⁷Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁸Seoul National University College of Medicine, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Nonsteroidal anti-inflammatory drugs or corticosteroids are first-line drugs for treating AOSD.…
Abstract Number: 1241 • ACR/ARHP Annual Meeting 2014
Efficacy of Tocilizumab Therapy in Korean Patients with Adults Onset Still’s Disease: Multicenter Retrospective Study of 20 Cases
Jin Ju Kim¹, Joo Hyun Lee², Chang-Nam Son³, Hyoun-Ah Kim⁴, Kwang-Hoon Lee⁵, Sang Tae Choi⁶, Eun Young Lee⁷, Ki Chul Shin⁸, Hoon-Suk Cha⁹ and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Ilsan Paik Hospital, Inje University, Goyang, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwan, South Korea, ⁵Dongguk University Ilsan Hospital, Goyang, South Korea, ⁶Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁷Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁸Rheumatology, Seoul National University College of Medicine, Seoul, South Korea, ⁹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Adult onset Still’s disease (AOSD) is a rare inflammatory disorder of unknown etiology. Refractory cases to conventional therapy require biologic agents. Although IL-1 targeting…
Abstract Number: 193 • ACR/ARHP Annual Meeting 2012
Tocilizumab in Adult Still’s Disease : The Israeli Experience
Ori Elkayam¹, Nizar Jiries², Zvi Dranitzki³, Shaye Kivity⁴, Merav Lidar⁵, Ofer Levy⁶, Mahmoud Abu-Shakra⁷, Hagit Sarvagil-Maman⁸, Hagit Padova⁸, Dan Caspi⁹ and Itzhak Rosner¹⁰, ¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel, ²Rheumatology, Bnai Zion Medical Center, Israel, ³Medicine, Hadassah hebrew university, Jerusalem, Israel, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, ⁵Medicine F, Sheba Medical Center, Ramat Gan, Israel, ⁶Rheumatology, Asaf Harofe Medical Center, ⁷Medicine and Rheumatology, Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹⁰Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel
Background/Purpose: The objective of this study was to review the clinical and laboratory characteristics of patients with adult's Still disease treated with tocilizumab (TCZ) in…

Abstracts tagged "Adult-onset Still’s disease and tocilizumab"

Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month

Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases

Efficacy of Tocilizumab Therapy in Korean Patients with Adults Onset Still’s Disease: Multicenter Retrospective Study of 20 Cases

Tocilizumab in Adult Still’s Disease : The Israeli Experience